ENO3 and hepatocellular carcinoma: Since Wnt/β-catenin signaling can enhance proliferation and migration rates and drug resistance of HCC cells, thus, ENO3 may serve as a Wnt/β-catenin axis inhibitor and a specific therapeutic target for the treatment of HCC.